The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Mexiletine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Butalbital. The therapeutic efficacy of Troglitazone can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Arsenic trioxide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Nortriptyline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Melperone. The risk or severity of adverse effects can be increased when Camazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when SJG-136 is combined with Olanzapine. Nefazodone may increase the serotonergic activities of Olanzapine. The serum concentration of Nilotinib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methapyrilene. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Sulfisoxazole. Olanzapine may increase the QTc-prolonging activities of Perflutren. The serum concentration of Ubidecarenone can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Protriptyline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone. The serum concentration of Olanzapine can be decreased when it is combined with Osimertinib. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Harmaline may increase the serotonergic activities of Olanzapine. The metabolism of Olanzapine can be decreased when combined with Dosulepin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Atorvastatin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine. The risk or severity of adverse effects can be increased when Clobazam is combined with Olanzapine. Olanzapine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etifoxine. Olanzapine may decrease the stimulatory activities of Methamphetamine. Olanzapine may increase the QTc-prolonging activities of Haloperidol. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Primidone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Agomelatine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fosphenytoin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tolcapone. Olanzapine may increase the QTc-prolonging activities of Clozapine. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Butethal. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trans-2-Phenylcyclopropylamine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclizine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Phenoxyethanol. The serum concentration of Mevastatin can be increased when it is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Asenapine. The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Olanzapine may increase the QTc-prolonging activities of Disopyramide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dapiprazole. The risk or severity of adverse effects can be increased when Triazolam is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Tranylcypromine. The metabolism of Olanzapine can be decreased when combined with Nevirapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrahydropalmatine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Melatonin. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Molindone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Clidinium. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorzoxazone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ropivacaine. The serum concentration of Cerivastatin can be increased when it is combined with Olanzapine. The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Olanzapine. Olanzapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone. The metabolism of Olanzapine can be decreased when combined with Simeprevir. The serum concentration of Olanzapine can be increased when it is combined with Deferasirox. The risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital. Olanzapine may increase the QTc-prolonging activities of Pentamidine. The metabolism of Olanzapine can be decreased when combined with Manidipine. The metabolism of Olanzapine can be decreased when combined with Clobazam. The risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Cinacalcet. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alphaprodine. The serum concentration of Pitavastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine. The serum concentration of Itraconazole can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The serum concentration of Thioridazine can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Flumazenil is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine. The risk or severity of adverse effects can be increased when Olanzapine is combined with 7-Nitroindazole. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine. Pargyline may increase the serotonergic activities of Olanzapine. The metabolism of Olanzapine can be decreased when combined with Rucaparib. The metabolism of Olanzapine can be decreased when combined with Midostaurin. Olanzapine may increase the QTc-prolonging activities of Anagrelide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Propofol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Benperidol. The risk or severity of adverse effects can be increased when PF-477736 is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Bupropion. Venlafaxine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate. Olanzapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloroprocaine. The risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant. The risk or severity of adverse effects can be increased when Metergoline is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Ceritinib. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amitriptyline. Pivhydrazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine. Olanzapine may increase the QTc-prolonging activities of Artemether. Phenoxypropazine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Propoxycaine. Olanzapine may increase the QTc-prolonging activities of Zuclopenthixol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trichloroethylene. Furazolidone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Midazolam is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Chloroquine. The metabolism of Olanzapine can be decreased when combined with Tipranavir. The therapeutic efficacy of Voglibose can be decreased when used in combination with Olanzapine. The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine. The serum concentration of Posaconazole can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amperozide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fexofenadine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline. The therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etidocaine. Caroxazone may increase the serotonergic activities of Olanzapine. The metabolism of Olanzapine can be decreased when combined with Isoniazid. The risk or severity of adverse effects can be increased when Nicergoline is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Olopatadine. Olanzapine may increase the QTc-prolonging activities of Propafenone. Sertraline may increase the serotonergic activities of Olanzapine. Nabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Milnacipran may increase the serotonergic activities of Olanzapine.